Bicara Therapeutics Inc.
Bicara Therapeutics Inc. (BCAX): 2 pipeline candidates · 1 upcoming catalyst · ~42 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
42.4 months
D/E 0.08 · 0% dilution
Lead: Phase 2/Phase 3
2 candidates
1 upcoming, next in ~1109d
1 buy · 33 sells (180d)
A transparent, data-derived signal for Bicara Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.4B
Cash
$323.5M
Quarterly Burn
$37.5M
Runway
42.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| ficerafusp alfa | Phase 2/Phase 3 |
| ficerafusp alfa (formerly BCA101) | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
144
Total value held
$1.06B
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 7,255,993 | $144.3M |
| janus henderson group plc | 6,666,136 | $132.5M |
| deep track capital, lp | 4,062,500 | $80.8M |
| vanguard capital management llc | 3,548,440 | $70.6M |
| red tree management, llc | 3,170,509 | $63.1M |
| blackrock, inc. | 2,843,707 | $56.6M |
| omega fund management, llc | 2,392,150 | $47.6M |
| royalty pharma sub-manager, llc | 2,388,150 | $46.7M |
| fmr llc | 2,100,929 | $41.8M |
| citadel advisors llc | 1,726,242 | $34.3M |
Showing top 10 of 144 institutional holders of Bicara Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Bicara Therapeutics Inc.'s pipeline?
Bicara Therapeutics Inc. (BCAX) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Bicara Therapeutics Inc.'s lead drug candidate?
Bicara Therapeutics Inc.'s most advanced tracked candidate is ficerafusp alfa (Phase 2/Phase 3) for Metastatic Head and Neck Squamous Cell Carcinoma.
What is Bicara Therapeutics Inc.'s next catalyst?
Bicara Therapeutics Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in C" — expected July 1, 2029.
What is Bicara Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Bicara Therapeutics Inc. has approximately 42.4 months of cash runway.
What is Bicara Therapeutics Inc.'s market capitalization?
Bicara Therapeutics Inc.'s market capitalization is approximately $1.4B.
Get the full picture on Bicara Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.